RxDoctor Payments Data

Nnamdi Nwabueze, MD

Internal Medicine · Jackson, LANPI 1871525667

Payments from drug & device makers

$675in general payments, 2019–2025

Across 31 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$267
  • Lilly USA, LLC$129
  • Merck$124
  • Pfizer$45
  • Abbott$29
  • Dexcom, Inc.$26
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$65697%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$675 in reported general payments places this provider in the 55th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$68,986
Medicare patients
118
Services billed
985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide354$451,687
MounjaroTirzepatide166$198,517
JanuviaSitagliptin Phosphate152$115,393
JardianceEmpagliflozin142$106,896
EliquisApixaban96$86,043
FarxigaDapagliflozin Propanediol90$83,582
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$76,518
Tresiba Flextouch U-200Insulin Degludec35$58,793
TrulicityDulaglutide63$58,188
TradjentaLinagliptin55$38,980
LinzessLinaclotide51$34,676
RybelsusSemaglutide12$25,857
Fiasp FlextouchInsulin Aspart (Niacinamide)12$25,025
EntrestoSacubitril/Valsartan13$23,862
Breo ElliptaFluticasone/Vilanterol41$22,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$267$477,545366 claims
Lilly USA, LLCMounjaro, Trulicity$129$256,705229 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Combivent Respimat, Stiolto Respimat$19$169,439239 claims
MerckJanuvia$124$115,393152 claims
PfizerEliquis$45$86,04396 claims
AbbVieLinzess$12$34,67651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Jackson

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →